EXZOLE-SB 130mg Capsules

Advanced antifungal therapy with enhanced bioavailability.

Antifungal

Anti-Fungal Division

Advanced Antifungal Therapy with Enhanced Bioavailability

Itraconazole SB (Super Bioavailable / Solid Dispersion formulation) offers enhanced bioavailability compared to conventional itraconazole capsules, requiring a lower dose (typically 50 mg or 65 mg SB equivalent to 100 mg standard) without requiring an acidic stomach environment for absorption.

Composition: Itraconazole Capsules IP 130 mg
Formulation: Supra Bioavailable (SB)
Class: Antifungal
Pack: 10 × 10 capsules
Division: Anti-Fungal

Specialties

Dermatology & VenereologyGeneral / Internal MedicineInfectious DiseasesPulmonologyGynecologyENT (Otorhinolaryngology)

Key Benefits

Enhanced bioavailability. Broad coverage.

Higher potencyHigher potency compared to conventional ITZ (itraconazole).
Broad-spectrum coverageBroad-spectrum antifungal coverage across a wide range of fungal infections.
Superior absorptionA super bio-available formulation for improved efficacy and consistent outcomes.

Pack Specifications

Pack & product details

As per the approved packaging artwork.

Product name: Exzole SB-130 — Itraconazole Capsules IP 130 mg (Supra Bioavailable Formulation)
Item: Unit Carton · Foil (Alu-Alu Blister)
GSM / Foil thickness: Carton 320 GSM · Foil 0.025 mm (DSO)
Board: FBB
Paper: Pack insert: 54 GSM Maplitho paper
Foil type: Alu Foil + HSL (4–6 GSM)
Strip size: 155 × 96 mm
Pack: 10 × 10 Capsules (carton) · 10 Capsules per blister
Composition: Each hard gelatin capsule contains: Itraconazole IP 130 mg, Excipients q.s. Approved colours used in capsule shells.

Clinical Applications

Cross-specialty clinical applications

How it is used across medical specialties.

Dermatology & Venereology

Dermatophytosis: Recurrent or extensive Tinea corporis, Tinea cruris, Tinea pedis, and Tinea manuum.
Onychomycosis: Fungal nail infections of fingernails and toenails (pulse or continuous therapy).
Pityriasis Versicolor & Cutaneous Candidiasis: Extensive or recalcitrant cutaneous fungal infections.

General / Internal Medicine & Infectious Diseases

Systemic & Endemic Mycoses: Histoplasmosis, Blastomycosis, and Aspergillosis (non-immunocompromised and mild-to-moderate immunocompromised patients).
Empirical & Maintenance Antifungal Therapy: Prophylaxis or treatment in neutropenic or immunocompromised hosts.

Pulmonology

Allergic Bronchopulmonary Aspergillosis (ABPA): Adjunctive treatment to corticosteroids to reduce fungal load in the airways.
Chronic Pulmonary Aspergillosis (CPA): Long-term suppressive management.

Gynecology

Recurrent Vulvovaginal Candidiasis (RVVC): Systemic management when topical azoles or single-dose fluconazole fail.

ENT (Otorhinolaryngology)

Fungal Rhinosinusitis: Adjunctive systemic antifungal cover for allergic fungal rhinosinusitis (AFRS) or invasive fungal sinusitis post-debridement.

Prescription medicine — CautionNot to be sold by retail without the prescription of a Registered Medical Practitioner.

Other Divisions